Clinical Trials Browser

Phase 1/2 × Amplified Fragment Length Polymorphism Analysis × Other hematologic neoplasm × Clear all

NCT01075321 2020-10-22

Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT01269385 2020-06-23

Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia

Phase 1/2 Completed

22 enrolled 9 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01165996 2019-03-04

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Phase 1/2 Completed

25 enrolled 13 charts

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Thrombocytopenia, Leukemia, Myelomonocytic, Chronic